129(B6)-Serpine1tm1Mlg Apoetm1Bres/CljH[cc]

Status

Available to order

EMMA IDEM:02066
International strain name129(B6)-Serpine1tm1Mlg Apoetm1Bres/CljH[cc]
Alternative nameApoE/PAI-1
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolSerpine1tm1Mlg,
Gene/Transgene symbolSerpine1

Information from provider

ProviderChristopher Jackson
Provider affiliationUniversity of Bristol
Genetic informationTargeted null mutation of the apolipoprotein E and Serpine1 (formerly plasminogen activator inhibitor-1, PAI-1) genes.
Phenotypic informationShortened life span.
Breeding historyMice were congenic on a 129 background.
References
  • Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.;Plump A S, Smith J D, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft J G, Rubin E M, Breslow J L, ;1992;Cell;71;343-53; 1423598
  • Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice.;Carmeliet P, Bouché A, De Clercq C, Janssen S, Pollefeyt S, Wyns S, Mulligan R C, Collen D, ;1995;Annals of the New York Academy of Sciences;748;367-81; discussion 381-2; 7695179

Information from EMMA

Archiving centreMary Lyon Centre at MRC Harwell, Oxford, United Kingdom
Animals used for archivinghomozygous 129
Breeding at archiving centreMales were archived at the time of arrival. No breeding was performed at the archiving centre. Males were understood to be homozygous congenic on a 129 background.

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

MGI phenotypes (allele matching)
  • abnormal digestive system physiology / MGI
  • increased circulating cholesterol level / MGI
  • abnormal circulating cholesterol level / MGI
  • xanthoma / MGI
  • atherosclerotic lesions / MGI
  • abnormal circulating LDL cholesterol level / MGI
  • abnormal cerebral cortex morphology / MGI
  • abnormal hippocampus morphology / MGI
  • abnormal neuron morphology / MGI
  • increased circulating VLDL cholesterol level / MGI
  • increased triglyceride level / MGI
  • increased susceptibility to atherosclerosis / MGI
  • decreased circulating HDL cholesterol level / MGI
  • increased circulating triglyceride level / MGI
  • heart inflammation / MGI
  • increased susceptibility to bacterial infection / MGI
  • cardiac fibrosis / MGI
  • liver fibrosis / MGI
  • liver/biliary system phenotype / MGI
  • abnormal enzyme/coenzyme activity / MGI
  • increased angiogenesis / MGI
  • increased sensitivity to induced morbidity/mortality / MGI
  • decreased susceptibility to endotoxin shock / MGI
  • decreased sensitivity to xenobiotic induced morbidity/mortality / MGI
  • increased granulocyte number / MGI
  • abnormal lung morphology / MGI
  • abnormal body weight / MGI
  • decreased body weight / MGI
  • weight loss / MGI
  • neoplasm / MGI
  • abnormal blood circulation / MGI
  • respiratory system inflammation / MGI
  • abnormal acute inflammation / MGI
  • enhanced wound healing / MGI
  • glomerulonephritis / MGI
  • increased urine protein level / MGI
  • increased acute inflammation / MGI
  • increased oxygen consumption / MGI
  • decreased triglyceride level / MGI
  • immune system phenotype / MGI
  • hematopoietic system phenotype / MGI
  • abnormal energy expenditure / MGI
  • increased body temperature / MGI
  • decreased angiogenesis / MGI
  • abnormal epididymal fat pad morphology / MGI
  • decreased circulating interleukin-6 level / MGI
  • abnormal interleukin level / MGI
  • decreased subcutaneous adipose tissue amount / MGI
  • decreased liver triglyceride level / MGI
  • glomerular crescent / MGI
  • hyperglycemia / MGI
  • abnormal kidney morphology / MGI
  • decreased circulating cholesterol level / MGI
  • abnormal renal glomerulus morphology / MGI
  • homeostasis/metabolism phenotype / MGI
  • increased blood urea nitrogen level / MGI

Literature references

  • Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.;Plump A S, Smith J D, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft J G, Rubin E M, Breslow J L, ;1992;Cell;71;343-53; 1423598
  • Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice.;Carmeliet P, Bouché A, De Clercq C, Janssen S, Pollefeyt S, Wyns S, Mulligan R C, Collen D, ;1995;Annals of the New York Academy of Sciences;748;367-81; discussion 381-2; 7695179

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
MTA will be issued after an order has been submitted.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).